readthroughSign in
Nov 12, 2026Quarterly update

Immix reports 89% complete response rate in NEXICART-2, plans mid-2027 BLA

The company said interim results across all 45 trial patients will be presented at ASH in December, while it continues preparing for a potential AL amyloidosis launch.

Immix Biopharma reported an update on its NXC-201 program and third-quarter 2026 financial results on November 12, 2026, covering the period ended September 30, 2026.

The company said an 89% complete response rate was reported across all 45 NEXICART-2 patients, with MRD-negativity indicating potential to reach up to 98% complete response rate in the future.1 Interim data from the trial are set to be shown at the American Society of Hematology meeting: NXC-201 NEXICART-2 interim clinical data will be presented at the 68th American Society of Hematology (ASH) Annual Meeting in New Orleans, LA, on Monday, December 14, 2026.1

On regulatory and trial timing, Immix plans to submit its BLA in mid-2027 and to start the NEXICART-3 front-line trial in the first half of 2027.1 The company also said it is moving forward with launch readiness work spanning commercial site activation, engagement with providers and payers, manufacturing, and education for healthcare professionals.1

Immix added two executives to support this work. David He was named Senior Vice President, Head of Technical Operations, having previously held senior roles contributing to two approved BCMA CAR-T therapies, CARVYKTI and FUCASO.1 Karin McIntosh was named Senior Vice President, Head of Regulatory Affairs, having worked on FDA programs including JANUVIA, EMFLAZA, ELZONRIS, and the 2026 approval of TREGZI.1

On finances, Immix reported $340.9 million in cash, cash equivalents, and marketable securities as of September 30, 2026, which the company said is expected to provide operating runway into mid-2028.1 Operating expenses for the quarter were $15.9 million.1 Immix also said it will present at the 45th Annual J.P. Morgan Healthcare Conference in San Francisco from January 11 to 14, 2027.1

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.